title: The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
abstract: Neuroblastoma, an embryonic cancer of the sympathetic nervous system, is the most common extracranial solid tumor in childhood. Dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma. However, the safe and effective use of dinutuximab therapy in these high-risk patients requires medical expertise in patient selection, treatment administration, and the monitoring and management of adverse events. Findings of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma. Multi-institutional nursing approaches to implementing standard protocols ensure the effective management of high-risk neuroblastoma patients receiving dinutuximab immunotherapy. Understanding and implementing recommendations for the management of the clinically important and most common adverse events are essential to ensuring patient continuation of therapy and improving patient outcomes.
authors.affiliation: 1 Children's Hospital Los Angeles, Los Angeles, CA, USA.
authors.forename: Rita
authors.initials: R
authors.lastname: Secola
authors.affiliation: 1 Children's Hospital Los Angeles, Los Angeles, CA, USA.
authors.forename: Araz
authors.initials: A
authors.lastname: Marachelian
authors.affiliation: 2 The University of Chicago Comer Children's Hospital, Chicago, IL, USA.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
authors.affiliation: 2 The University of Chicago Comer Children's Hospital, Chicago, IL, USA.
authors.forename: Bonnie
authors.initials: B
authors.lastname: Toy
authors.affiliation: 3 Arkansas Children's Hospital/University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Neville
authors.affiliation: 4 Cook Children's Medical Center, Fort Worth, TX, USA.
authors.forename: Meaghan
authors.initials: M
authors.lastname: Granger
authors.affiliation: 4 Cook Children's Medical Center, Fort Worth, TX, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Brentlinger
authors.affiliation: 5 Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO, USA.
authors.forename: Gina
authors.initials: G
authors.lastname: Martin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D060046:Maintenance Chemotherapy / Q000451:nursing*; D009447:Neuroblastoma / Q000188:drug therapy* / Q000451:nursing*; D024802:Nurse's Role
chemical_list: D000911:Antibodies, Monoclonal; C112746:dinutuximab
keywords: adverse events; dinutuximab; neuroblastoma; pediatric